Industry
Cancer Intelligence Care Systems, Inc.
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(33.3%)
Phase 2
1(33.3%)
Phase 1
1(33.3%)
3Total
N/A(1)
Phase 2(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT06603987Phase 1Enrolling By Invitation
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Role: collaborator
NCT05601232Phase 2Active Not Recruiting
A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA
Role: collaborator
NCT04293289Not ApplicableCompleted
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
Role: lead
All 3 trials loaded